Novartis' Diovan Gets EU Nod for Treatment of Heart Attack Survivors

Novartis AG has successfully completed the EU Mutual Recognition Procedure (MRP) in 14 countries for Diovan (valsartan) for the treatment of heart attack survivors. According to the company release, Diovan, a proven, powerful antihypertensive agent, is now indicated as a potentially life-saving therapy for the more than 7.50 lakh people in the EU who are at risk of a recurrent heart attack or other serious outcomes such as cardiovascular mortality, hospitalization for heart failure, resuscitated cardiac arrest or stroke.
Pharmabiz